Topic Simvastatin for Bone Regeneration
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Simvastatin, Simvastatin 10 mg, Simvastatin Placebo.
- Who it may be relevant to
- Registry conditions: Dimensional Changes, Bone Density. Basic parameters: 18 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy of Topical Application of Simvastatin in Bone Regeneration
Overview
The goal of this clinical trial is to evaluate the efficacy of topical application of simvastatin in bone regeneration in the maxillae, in the reduction of dimensional bone changes, using mandibular third molar surgery as a model and assessing bone healing at 12 weeks. We will also compare the two forms of intralveolar topical administration currently used to assess which is the best form of administration. The main questions it aims to answer are: * Can the topical application of simvastatin, used as a preservation material, improve the variations with respect to bone dimensions and density that occur after tooth extraction. * Can topical application of SM improve soft tissue healing. * Does the topical application of SM produce changes with respect to postoperative variables of pain, inflammation or trismus. * What is the best vehicle for topical SM administration? For this purpose, the investigators will randomly place 4 topical treatment options in the postextraction alveoli: * SM in gel form * collagen sponge impregnated with saline solution containing 10 mg of SM * collagen sponge with placebo gel. All patients will undergo postoperative CBCT, which will be repeated at 12 weeks. In addition, inflammation, trismus and pain variables will be measured preoperatively, at 24 hours, 3 and 7 days.
Detailed description
The study design is a double-blind randomized clinical trial (RCT). The study population consisted of patients referred to the Master's Degree in Oral Surgery and Implantology of the Faculty of Dentistry of the UGR (Granada) with an indication for surgical extraction of mandibular third molars.
A sample of 90 third molars will be used to establish a confidence level of 95% and a power of 90%. The sample will be divided into 3 groups of 30 each. Group I: 30 mandibular third molars in which gel with 1.2% simvastatin is used for healing. Group II: 30 mandibular third molars in which a collagen sponge impregnated with saline solution containing 10 mg of the active ingredient simvastatin is used for healing. Group III: 30 mandibular third molars in which a collagen sponge impregnated in gel without SM is used for healing.
SURGICAL PROCEDURE:
Extraction will be performed only of included mandibular third molars. For this purpose we will anesthetize the lower dental nerve, lingual nerve and buccal nerve using 4% articaine with epinephrine by means of the truncular technique.
The intervention will be performed by flap lifting, ostectomy with handpiece and round bur, or odontosection with turbine whenever the case requires it. The socket will be curetted and washed with physiological saline solution to ensure that no surgical debris remains. After this, we will proceed to place in the socket the combination of material chosen by randomization (simvastatin gel, gel without simvastatin, collagen sponge with simvastatin or only collagen sponge). Once the filling material has been placed, we will proceed to the primary closure of the wound with 3.0 silk. We will place a gauze with 0.20% chlorhexidine gel at the end of the extraction, for the patient to keep it for 30 minutes. We will indicate to the patient the appropriate postoperative care and we will prescribe 0.12% chlorhexidine mouthwash for rinsing after brushing. One week later, the patient will be seen to remove the suture.
Postoperative medication:
* Antibiotic treatment: amoxicillin 750 mg 1 every 8 hours, for 7 days. In case of allergy to penicillin, the drug of choice will be clindamycin 300 mg 1 every 8 hours. * Analgesic and anti-inflammatory treatment: ibuprofen 400 mg 1 every 8 hours for two days, from the third day on demand. Rescue paracetamol 1 g.
VARIABLES TO BE STUDIED
Primary Variables:
The primary variable to be studied will be the dimensional changes
Secondary variables:
The secondary variables to be studied will be bone density measured in Hounsfield units , soft tissue healing, pain and analgesia, inflammation and trismus.
Interventions
- Drug Simvastatin
Simvastatin gel with 1.2% simvastatin - Drug Simvastatin 10 mg
sponge of collagen impregned in saline solution with 10 mg of simvastatin - Drug Simvastatin Placebo
Collagen sponge impregned in simvastatin placebo gel without simvastatin
Primary outcome measures
- Dimensional changes [Time frame: From the time of extraction to when bone regeneration is supposed to be completed 12 weeks later.]
Secondary outcome measures (1)
- Bone density [Time frame: Postextraction to the end of bone regeneration at 12 week latter]
Eligibility criteria
Inclusion criteria
- Anesthetic risk ASA I-II.
- Patients with the adjacent tooth in the mouth (37 or 47).
- Third molars with fully developed roots.
- Mandibular third molars included or semi-included.
- With indication for extraction.
- Signed informed consent.
Exclusion criteria
- Pregnant or lactating women.
- Chronic smokers.
- Patients with decompensated metabolic disease.
- Patients with motor difficulties that prevent or hinder hygiene.
- Patients who are using statins to treat hypercholesterolemia.
- Patients under treatment with drugs that could affect the osseointegration process such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.
- Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Spain · 1 center
- UGranada — Granada
Publications
- Degala S, Bathija NA. Evaluation of the Efficacy of Simvastatin in Bone Regeneration after Surgical Removal of Bilaterally Impacted Third Molars-A Split-Mouth Randomized Clinical Trial. J Oral Maxillofac Surg. 2018 Sep;76(9):1847-1858. doi: 10.1016/j.joms.2018.04.035. Epub 2018 May 31. PMID 29859160
- Cruz R, Moraschini V, Calasans-Maia MD, de Almeida DCF, Sartoretto SC, Granjeiro JM. Clinical efficacy of simvastatin gel combined with polypropylene membrane on the healing of extraction sockets: A triple-blind, randomized clinical trial. Clin Oral Implants Res. 2021 Jun;32(6):711-720. doi: 10.1111/clr.13740. Epub 2021 Mar 27. PMID 33715258
- Deepanjali M, Prasad TS, Manodh P. Efficacy of simvastatin in bone regeneration after surgical removal of mandibular third molars. Oral Maxillofac Surg. 2023 Sep;27(3):427-432. doi: 10.1007/s10006-022-01081-y. Epub 2022 Jun 1. PMID 35648294
- Diniz JA, Barbirato DDS, do Nascimento EHL, Pontual ADA, Dourado ACAG, Laureano Filho JR. Tomographic evaluation of the effect of simvastatin topical use on alveolar bone microarchitecture, pain and swelling after mandibular third molar extraction: a randomized controlled trial. Clin Oral Investig. 2022 Apr;26(4):3533-3545. doi: 10.1007/s00784-021-04322-8. Epub 2022 Jan 22. PMID 35064813
Identifiers
NCT: NCT07031778 · 3904/CEIH/2023 · 3904/CEIH/2023